BAMLET in the drinking water; protection against intestinal cancer and potent beneficial health effects

Colorectal cancer is a leading cause of death world-wide and more than 180,000 cases are diagnosed annually in the US alone. We now show that daily, long-term treatment with BAMLET in the drinking water inhibits intestinal tumor development in mice genetically susceptible to intestinal tumors, compared to mice not receiving BAMLET. The frequency of tumors and the tumor size was reduced already after short-term BAMLET treatment but with continued treatment, the mice remained symptom-free and survived significantly longer than control mice.

Targeting early, locally growing tumors is essential to reduce the risk for tumor progression and metastatic disease. Surgery may be highly efficient and remove the tumor permanently, but chemotherapy is often required, as well, potentially creating severe side effects in treated patients. BAMLET, in contrast, targeted the tumor rather than healthy intestinal tissue and did not cause side effects in the mice that developed cancer or in healthy mice that received BAMLET in the drinking water.

Without treatment, the intestinal tumors grew aggressively and the majority of untreated mice showed evidence of disease also in the lungs, liver and kidneys. BAMLET treatment protected the mice from these extra-intestinal   manifestations of disease. These findings are conceptually important, as they suggest that local treatment of the intestine, by supplying BAMLET in the drinking water, can affect cancer development as well as disease states that the cancer may cause in other organs, suggesting a systemic as well as a local effect.

The effects of BAMLET treatment further included important physiological functions, which positively affectedlipid metabolism and glucose metabolism. The findings highlight the beneficial properties of BAMLET and a broad range of effects affecting health and disease.  

A patent covering the new findings has recently been filed.

‘’The BAMLET findings confirm the strength and versatility of our compounds HAMLET, Alpha1H and BAMLET”, says Catharina Svanborg, Professor and Founder of Hamlet Pharma.

‘’These findings strengthen our focus on BAMLET drug development’’, says Martin Erixon, CEO of Hamlet Pharma.

This disclosure contains information that Hamlet is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 09-11-2022 14:44 CET.